Virtual Library
Start Your Search
Yoshiko Fujita
Author of
-
+
P2.04 - Immuno-oncology (ID 167)
- Event: WCLC 2019
- Type: Poster Viewing in the Exhibit Hall
- Track: Immuno-oncology
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
-
+
P2.04-62 - TCR Repertoire Analysis of Peripheral CD8+PD-1+ T Cells Is Effective as a Predictive Biomarker for Response to the Immune Checkpoint Inhibitor (ID 1668)
10:15 - 18:15 | Author(s): Yoshiko Fujita
- Abstract
Background
Immune checkpoint inhibitors are effective in NSCLC patients. As patient selection is important, many biomarkers have been studied. We developed a method to predict the effect of immune checkpoint inhibitors using peripheral blood. Tumor infiltrating lymphocyte (TIL) sensitizes to neoantigens, some of them migrate to peripheral blood. We measured tumor mutation burden (TMB) of resected specimen and T-cell receptors (TCRs) diversity of peripheral CD8+PD-1+ T cells, examined response rate and prognosis.
Method
The study included NSCLC patients who relapsed after surgery and chemotherapy failed. Peripheral blood mononuclear cells (PBMC) was collected from patients before 1st administration of nivolumab. CD8+PD-1+ T cells were subjected to FACS sorting, NGS-based TCR repertoire analysis was performed by Repertoire Genesis Inc., and TCR diversity was evaluated statistically.
Result
There were no differences in the proportion of PD-1+ in CD8+ T cells between responders and non-responders. TCR α diversity based on DE50 was significantly higher among responders than non-responders (P < 0.01). TCR β diversity was also significantly higher among responders than non-responders (P < 0.01). Progression-free survival (PFS) and Overall survival (OS) were better in TCR diversity high group than that TCR diversity low group (P=0.01). TMB was not significantly different between responder and non-responder. PFS and OS were not significantly different between TMB high (≧10) group and TMB low (<10) group.
Conclusion
Significant therapeutic effect of nivolumab was observed in NSCLC patients whose peripheral CD8+ PD-1+ T cells had highly diverse TCR. This study suggests the TCR diversity of peripheral CD8+PD-1+ T cells is effective as a predictive biomarker for response to the immune checkpoint inhibitor.